Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults

References

• Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents MMWR April 10, 2009 / Vol. 58 / No. RR-4.
   Google Scholar
• ECDC SIIP Team. ECDC guidance Priority risk groups for influenza vaccination. Stockholm, August 2008.
   Google Scholar
• Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52:122 - 7; http://dx.doi.org/10.1093/cid/ciq003; PMID: 21148530
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138 - 46; http://dx.doi.org/10.1093/cid/ciq019; PMID: 21148532
   PubMed Web of Science ®Google Scholar
• Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, et al, CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011; 6:e17758; http://dx.doi.org/10.1371/journal.pone.0017758; PMID: 21512577
   PubMed Web of Science ®Google Scholar
• Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J Clin Invest 1993; 92:2587 - 96; http://dx.doi.org/10.1172/JCI116873; PMID: 8254016
   PubMed Web of Science ®Google Scholar
• Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. [Erratum in: J Immunol 1994;152:376] J Immunol 1993; 151:6535 - 45; PMID: 7504023
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755 - 63; http://dx.doi.org/10.1016/j.vaccine.2007.06.066; PMID: 17692438
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614 - 9; http://dx.doi.org/10.1016/j.vaccine.2008.09.078; PMID: 18930093
   PubMed Web of Science ®Google Scholar
• Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13; http://dx.doi.org/10.1186/1741-7015-7-13; PMID: 19341446
   PubMed Web of Science ®Google Scholar
• Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346 - 54; http://dx.doi.org/10.4161/hv.6.4.10961; PMID: 20372053
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.06.010; PMID: 21699951
   PubMed Web of Science ®Google Scholar
• Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin 2010; 6:336 - 45; http://dx.doi.org/10.4161/hv.6.4.10753; PMID: 20372083
   PubMed Web of Science ®Google Scholar
• Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Ther 2011; 28:640 - 9; http://dx.doi.org/10.1007/s12325-011-0042-0; PMID: 21751080
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, Ellefsen K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248 - 56; http://dx.doi.org/10.1093/cid/ciq104; PMID: 21288852
   PubMed Web of Science ®Google Scholar
• Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011; 29:9209 - 13; http://dx.doi.org/10.1016/j.vaccine.2011.09.103; PMID: 21974995
   PubMed Web of Science ®Google Scholar
• Soonawala D, Rimmelzwaan GF, Gelinck LBS, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011; 6:e16496; http://dx.doi.org/10.1371/journal.pone.0016496; PMID: 21304982
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493 - 504; http://dx.doi.org/10.1016/S1473-3099(09)70175-6; PMID: 19628174
   PubMed Web of Science ®Google Scholar
• Ho DD. HIV-1 viraemia and influenza. Lancet 1992; 339:1549; http://dx.doi.org/10.1016/0140-6736(92)91321-X; PMID: 1351231
   PubMed Web of Science ®Google Scholar
• Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999; 28:541 - 7; http://dx.doi.org/10.1086/515170; PMID: 10194075
   PubMed Web of Science ®Google Scholar
• Couch RB. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999; 28:548 - 51; http://dx.doi.org/10.1086/515171; PMID: 10194076
   PubMed Web of Science ®Google Scholar
• Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253 - 9; http://dx.doi.org/10.1128/CVI.00316-07; PMID: 18003811
   PubMed Web of Science ®Google Scholar
• Yanagisawa N, Maeda K, Ajisawa A, Imamura A, Suganuma A, Ando M, et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 2011; 29:5694 - 8; http://dx.doi.org/10.1016/j.vaccine.2011.06.003; PMID: 21689709
   PubMed Web of Science ®Google Scholar
• Zambon M. Laboratory diagnosis of influenza. In: Textbook of influenza. Nicholson KG, Webster RG, Hay AJ (editors). Oxford: Blackwell Science; 1998. pp. 291–313.
   Google Scholar
• World Health Organization Global Influenza Programme. WHO manual on animal influenza diagnosis and surveillance; 2002. WHO/CDS/NCS/2002/5.
   Google Scholar